NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
Clinical Trials
10 trialsNCT06012383 2023-08-25
AlvocadeĀ® (Bortezomib) Safety and Effectiveness Study
NanoAlvand
Completed
NCT02474563 2015-06-30
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
Janssen Korea, Ltd., Korea
Completed
NCT00440479 2015-04-16
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Janssen-Cilag B.V.
Completed
NCT01021592 2014-12-23
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
Janssen Korea, Ltd., Korea
Completed
NCT01026701 2014-04-28
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
Janssen Korea, Ltd., Korea
Completed
NCT00440765 2014-01-14
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
Janssen-Cilag B.V.
Completed
NCT00440635 2013-04-16
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
Janssen-Cilag International NV
Completed
NCT01030302 2013-03-08
A Retreatment Study With Bortezomib for Multiple Myeloma
Janssen Korea, Ltd., Korea
Completed
NCT01005628 2013-02-20
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
Janssen Korea, Ltd., Korea
Completed